NCT04083599 2026-04-08GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsGenmabPhase 1/2 Active not recruiting350 enrolled
NCT07020221 2026-04-03A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsVerastem, Inc.Phase 1/2 Recruiting295 enrolled
NCT07397338 2026-03-30Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRevolution Medicines, Inc.Phase 1/2 Recruiting370 enrolled
NCT06917079 2026-03-23BBO-11818 in Adult Subjects With KRAS Mutant CancerTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1 Recruiting387 enrolled
NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06704724 2026-03-13A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.PfizerPhase 1 Active not recruiting30 enrolled
NCT06447662 2026-02-25A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.PfizerPhase 1 Recruiting330 enrolled